IR-MED, Inc. News Releases

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

Mon, 03 Nov 2025 16:30:00 -0500

DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be approximately$10 billion globally1Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device developer, today announced that it has initiated the first-in-human clinical trial of its DiaSafe™ device – built on the...

IR-MED's Key Clinical and Media Milestones

Mon, 27 Oct 2025 16:05:00 -0400

PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel visibility push Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that...

IR-MED Investor Update Letter - Sept-2025

Tue, 16 Sep 2025 16:05:00 -0400

Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today published an investor update. Dear Valued Investors,As we enter September 2025, in addition to Q2 financial reports and to the 8K recently published, I find it appropriate to update you on the developments within our Company. As you will see from...

IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones

Mon, 23 Jun 2025 08:30:00 -0400

PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdownTechnology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tonesResults presented at HCA Healthcare & Galen College of Nursing Research Day; additional data to be featured at a podium session at the 2025 ANCC Magnet/ANE Research SymposiumRosh Pina, Israel--(Newsfile Corp. - June 23, 2025) - As the U.S....

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

Mon, 05 May 2025 08:30:00 -0400

DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foot ulcers can be prevented with early assessment, improving patient care and healthcare economics in a $10 billion global treatment market $500,000 grant underscores continued confidence in IR-MED's noninvasive "Sensing the Invisible" technology platformRosh Pina, Israel--(Newsfile Corp. - May 5,...